Multiple Sclerosis Foundation

On Demand Audio

View More Tracks

Data: Ocrevus treatment reduced MS disability progression

September 18, 2019

Results suggest earlier treatment with Ocrevus reduced the risk of disability progression and this effect was sustained over time. Additionally, new safety data remain consistent with the medicine’s favorable benefit-risk profile.

Learn more

Ocrevus biomarker data may improve understanding of MS progression

September 12, 2019

Researchers found that blood neurofilament light chain levels were significantly lowered following Ocrevus treatment in analyses of Phase III studies in relapsing and primary progressive MS.

Learn more